IASLC Lung Cancer News (ILCN), May 2022
ILCN | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Table of Contents
  • Alternative Dosing Strategies for Immune Checkpoint Inhibitors
  • US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective
  • Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes
  • Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System
  • Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award Lecture
  • In Brief for May 25, 2022
  • Financial Toxicity of Lung Cancer in the Netherlands
  • As Treatment Options in Lung Cancer Have Expanded, so Have Costs
  • Small, High PLCG2-Expressing Intratumoral Cells May Drive Metastasis
  • COAST Data Support Further Research of Immunotherapy Combinations
  • IASLC Responds to Call for Evidence
  • In Brief for May 11, 2022
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC). 

Click here to link to Submission Guidelines.
Powered By